Insight

Aakash Desai: A Year of Remarkable Progress in Lung Cancer and Mesothelioma Treatments

Aakash Desai/LinkedIn

Dec 11, 2024, 17:56

Aakash Desai: A Year of Remarkable Progress in Lung Cancer and Mesothelioma Treatments

Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, posted on LinkedIn:

“A Year of Remarkable Progress in Lung Cancer and Mesothelioma Treatments.

2024 has truly been an amazing year for advancements in Lung Cancer and Mesothelioma therapies.

Each month has brought groundbreaking FDA approvals, showcasing relentless efforts by researchers, clinicians, and the entire oncology community.

This chart vividly captures the monthly milestones in FDA drug approvals—a testament to how far we’ve come in delivering hope to patients battling these challenging diseases.

Key Highlights:

February: Approvals for Osimertinib combined with chemotherapy and Tepotinib, focusing on metastatic EGFR-mutated non-small cell lung cancer (NSCLC) and MET exon 14 skipping mutations.
March: Amivantamab-vmjw with chemotherapy received approval for NSCLC with EGFR exon 20 insertion mutations.
April: Alectinib was approved as an adjuvant treatment for ALK-positive NSCLC.
May: Tarlatamab-dlle brought hope for extensive-stage small cell lung cancer (SCLC) after progression.
August: Combination therapy featuring Lazertinib and Amivantamab was approved for locally advanced/metastatic NSCLC with EGFR mutations, alongside Durvalumab for resectable NSCLC as neoadjuvant/adjuvant therapy.
September: A pivotal month with approvals for Osimertinib (unresectable Stage III NSCLC), Amivantamab-vmjw with chemotherapy (EGFR exon 19/21 mutations), and Pembrolizumab for unresectable advanced mesothelioma.
October: Nivolumab for resectable NSCLC as neoadjuvant/adjuvant therapy.
December: Closing the year strong with approvals for Durvalumab (limited-stage SCLC) and Zenocutuzumab-zbco (NRG1 fusion-positive NSCLC).

This progress reaffirms the power of innovation, collaboration, and patient-centered research in oncology.

Each approval represents not just a new treatment, but a step closer to improved survival and quality of life for patients.

Let’s take a moment to appreciate the scientific rigor and dedication that went into each of these milestones.

It’s truly a global effort, involving clinicians, scientists, advocates, and industry leaders.”

Aakash Desai Amivantamab cancer FDA lazertinib Lung cancer Mesothelioma Treatments nivolumab NSCLC OncoDaily Oncology osimertinib SCLC tepotinib UAB O'Neal Comprehensive Cancer Center

Giuliana Rancic and Breast Cancer: How She Went Against, How She Survived, and More

Vincent Rajkumar: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma

"The Doctor Who Always Has Candies in His Pocket": A Conversation with Professor Guangchao Zhang, Pioneer of Pediatric Surgical Oncology in China

Highlights from Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer - Day 3

Wanda Sykes and Breast Cancer: How She Went Against, How She Survived, and More

Special Coverage